Cipla has launched an innovative combination ... tenofovir 300 mg and emtricitabine 200mg comprise the drug Viraday. Viraday, one tablet of which alone effectively treats a HIV infected person ...

The shares of Cipla rocketed almost 10 per cent on the NSE (National Stock Exchange) after pharmaceutical titan's goa ...

Learn more› By Roderick Scott and Ryan Whitwam After a new round of testing, we’ve added the 2024 Amazon Fire HD 8 tablet as our budget pick and added Samsung’s Galaxy Tab S10+ to the ...

Please verify your email address. Android tablets continue to flourish as the go-to devices for surfing the web, streaming shows, and even reading books, and the technology behind them is only ...

Shares of Cipla Ltd advanced 3 per cent in Monday's trade after the drugmaker announced a VAI status for its Goa unit, which ...

Cipla’s revenue reached Rs. 7,051 crore, reflecting a 7% y-o-y increase and a 6% q-o-q rise, meeting our expectations. EBITDA stood at Rs. 1,886 crore with 15% y-o-y growth; it slightly missed ...

The difference between a good tablet and a bad one can be stark. Our tough independent tests weed out the models to avoid and our expert buying advice will help you choose a winner. Use the results of ...

Cipla shares surged 9.88% after USFDA gave Goa facility VAI status. VAI status crucial for Cipla's new launches like Abraxane generic. Stock traded above some SMAs; RSI at 45.75 indicates neutral ...

Drug major Cipla Ltd said its Vice Chairman and Non-Executive Director MK Hamied has resigned from the company due to "age and health". "Vide letter dated 3rd September 2024, effective close of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Oct 30 (Reuters) - Indian shares fell on Wednesday, dragged down by high weightage financials and as drugmaker Cipla extended its post-results losses. Nine of the 13 major sectors logged losses.